Clinical trial
A Phase 2a, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of RVT-1201 in Patients With Pulmonary Arterial Hypertension
NCT03924154 is registered in ClinicalTrials.gov with Altavant Sciences GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of RVT-1201 in Patients With Pulmonary Arterial Hypertension
- Lead sponsor
- Altavant Sciences GmbH
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 1, 2019
- Completion date
- February 24, 2020
- Enrollment
- 3 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.